A systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy
Background Non-proliferative and proliferative diabetic retinopathy are common complications of diabetes and a major cause of sight loss. Anti-vascular endothelial growth factor drugs represent a treatment option for people with diabetic retinopathy and are routinely used to treat various other eye...
Saved in:
Main Authors: | Robert Hodgson, Matthew Walton, Helen Fulbright, Laura Bojke, Ruth Walker, Alexis Llewellyn, Sofia Dias, Lesley Stewart, David Steel, John Lawrenson, Tunde Peto, Mark Simmonds |
---|---|
Format: | Article |
Language: | English |
Published: |
NIHR Journals Library
2025-01-01
|
Series: | Health Technology Assessment |
Subjects: | |
Online Access: | https://doi.org/10.3310/NHYK3694 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study
by: Debdulal Chakraborty, et al.
Published: (2025-01-01) -
Vascular Endothelial Growth Factor (VEGF) as a Biomarker for Cancer-Associated Venous Thrombosis: A Meta-analysis
by: Alison M. Brown, et al.
Published: (2025-01-01) -
Visual Acuity Outcomes and Influencing Factors in a Cohort of UK Real-World Diabetic Macular Oedema Patients During the First Two Years of Anti-VEGF Treatment
by: Qing Wen, et al.
Published: (2025-01-01) -
Combination therapy of intravitreal ranibizumab and sub-tenon triamcinolone for treatment of resistant diabetic macular edema: a clinical study in Egypt
by: Hossam Eldin M. A. Khalil, et al.
Published: (2025-01-01) -
Analysis of Salivary Cytokines in Retinopathy of Prematurity
by: Hwa-Shiu Wu, et al.
Published: (2025-01-01)